Phase 2 Ovarian Cancer trials recruiting now

All Ovarian Cancer trials, every phase

Other phases for Ovarian Cancer

Phase 2 Ovarian Cancer trials

• 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
  NCT07189871 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
  NCT06503146 · Phase: Phase 2 · Ages: 18 Years to 120 Years · Sex: All (male and female) · 1 location
• A Beta-only IL-2 ImmunoTherapY Study
  NCT05086692 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 27 locations
• A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
  NCT07109726 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 36 locations
• A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
  NCT06695845 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 56 locations
• A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
  NCT04657068 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 164 locations
• A Study of DC05F01 in Chinese Patients with Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors
  NCT06873555 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
  NCT05377996 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 26 locations
• A Study of MT-4561 in Patients With Various Advanced Solid Tumors
  NCT06943521 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 18 locations
• A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
  NCT06395519 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 28 locations
• A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
  NCT06051695 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor
  NCT07612891 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
  NCT07610798 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
  NCT04503265 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
  NCT02830724 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 72 Years · Sex: All (male and female) · 1 location
• Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
  NCT03412877 · Phase: Phase 2 · Ages: 18 Years to 72 Years · Sex: All (male and female) · 2 locations
• Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
  NCT05000294 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 1 location
• Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors
  NCT00722228 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
  NCT04752826 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 25 locations
• Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
  NCT07410494 · Phase: Phase 1, Phase 2 · Ages: 8 Years to 85 Years · Sex: All (male and female) · 3 locations
• EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
  NCT07410676 · Phase: Phase 1, Phase 2 · Ages: No age limits stated · Sex: All (male and female) · 1 location
• Early Phase Study of KESONOTIDE™in Participants With Solid Tumours
  NCT06926075 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
  NCT06303505 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 29 locations
• Lead-212 PSV359 Therapy for Patients With Solid Tumors
  NCT06710756 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 90 Years · Sex: All (male and female) · 22 locations
• Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
  NCT05735080 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 18 locations
• Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT
  NCT06412510 · Phase: Phase 1, Phase 2 · Ages: 65 Years and older · Sex: All (male and female) · 1 location
• Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
  NCT06580002 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
  NCT07447050 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors
  NCT07586826 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• SL-28 for Advanced Solid Tumours
  NCT07341737 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
  NCT05489211 · Phase: Phase 2 · Ages: 18 Years to 130 Years · Sex: All (male and female) · 96 locations
• Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments
  NCT06799637 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 24 locations
• TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma
  NCT04969315 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
  NCT04585750 · Phase: Phase 1, Phase 2 · Ages: 12 Years and older · Sex: All (male and female) · 154 locations
• Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
  NCT03755739 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies
  NCT07064018 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Trop2-targeted immunoPET Imaging of Solid Tumors
  NCT06851663 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location

Common questions

What does Phase 2 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.